Abby Reisinger

Comms @wearehims
@NorthwesternU and @Apple and @Color alum.
Runner, reader, writer.

[andrewdudum @AndrewDudum]

@dranantmd is the clinical voice this conversation needs. Glad to have him sharing real-world experiences at the FDA this week.

[andrewdudum @AndrewDudum]

Today, we closed our acquisition of Eucalyptus, advancing our position as the world’s largest consumer health platform.

When @_Timdoyle and I first met, healthcare looked very different (and so did our lives - I was a first-time dad, still on paternity leave when we had our first lunch). Proactive healthcare still felt niche and the concept of direct-to-consumer access was misunderstood as a trend.

Five years later, the world has changed (and so has life – I’m now a dad to three boys, and Tim’s a father, too). People are no longer willing to navigate through arbitrary barriers for the simplest kinds of care. Healthcare innovators like drugmakers and diagnostic companies have realized connecting directly with individuals is the most powerful way to grow.

But what has stayed the same is how aligned Tim and I are on what the future of health can and should be. It’s simple, deeply personal, and built for everyday life. It became clear at the end of last year that the time has never been more right to come together.

Today, we’re operating as one company, focused on reaching millions of people around the world with a version of health that feels like a luxury, but doesn’t cost like one. Combining Eucalyptus’ local expertise with our scale means we can serve millions of people around the world and expand the network effects of the platform. We’ll become an everyday health companion and a partner to other healthcare innovators who want to build long-term relationships with their customers.

I told the entire team this morning: The most enduring consumer companies are the ones that create a completely new way of experiencing the most personal parts of our lives. My kids deserve a different version of health than I got. So do Tim’s. So do yours. That’s what we’re building at Hims & Hers and I can’t wait for the world to see what’s possible.

https://t.co/XIampqFSST

Read more here, including important footnotes and disclaimers: https://t.co/4A919nDjTO

[andrewdudum @AndrewDudum]

I spoke with @washingtonpost about what’s coming next for us, and we covered everything from GLP-1s to supplements to biological age to peptides. But the bigger picture is how we can create better access to the things that can help anyone feel great.

Thanks @PostRowland for a great conversation about what’s coming next in health and how we’re building it at Hims & Hers.

[andrewdudum @AndrewDudum]

Customer access should move at the same speed as innovation. When the healthcare industry works together to reach individuals, it does.

Since last week, thousands of people have signed up for our Wegovy® waitlist. Starting today, eligible Hims & Hers customers can start their journeys with @novonordisk’s FDA-approved Wegovy® Pill & Wegovy® Pen and partner with their provider on a comprehensive weight loss program designed to help them achieve their goals.

We take our role as the largest global consumer health platform seriously, and I can’t wait to keep finding ways to make sure everyone can access the tools they need to feel great.

Read more below from Dr. Craig, our Head of Weight Loss, on what’s available today. (And if you’re starting your Wegovy journey with us today, tag me and tell me how it’s going!)

More details, including important info, here: https://t.co/zBQXvwHnIt

[andrewdudum @AndrewDudum]

Tonight, when our ad airs during the Big Game, we will continue a much-needed conversation around what healthcare should look and feel like in America: affordable, proactive, personalized.

When we start hard conversations, we expect challenges along the way. But we won't ever stop advocating for better until the system becomes better for everyone.

https://t.co/iXmFwEkw0N

[andrewdudum @AndrewDudum]

To our customers (both future and current):

I have always believed that in order to change something, you have to be willing to have a tough conversation. We’ve done that as a company since we launched in 2017 because we know progress requires honesty before it provides hope.

Our latest ad, which will air at the big game next weekend, is meant to provoke a long overdue tough conversation. It’s meant to recognize that you deserve better. No one should be satisfied with a system that requires you to get sick before you’re allowed to get healthy.

This isn’t about advertising any one specific treatment. This is about speaking directly to you about the future we know all Americans deserve, whether you live in a rural community, a big city, or somewhere in between. This is about being a loud, unapologetic advocate for what we know care can and should look like for everyone in this country: affordable, proactive, and built to empower the individual.

In order for health outcomes in the US to really improve, we have to stop gatekeeping innovative, proactive tools and care. Real, lasting health requires having access to transparent information *and* innovation that can help prevent - not just treat - disease.

Meaningful change requires two things: the conviction to reimagine a better way and the stamina to make it a reality. My promise to all of you is that I’ll make sure Hims & Hers always has both.

Let’s close the health gap.

[andrewdudum @AndrewDudum]

Healthcare in 2026 will be defined by a simple truth: the individual is everything.

Based on how we’ve seen our customers succeed and the rapid rate of innovation, I think three things are likely to happen this year:

Direct-to-consumer channels will become one of the most important levers for players across the industry.
Longevity will become a critical part of mainstream health and wellness.
AI will become the great equalizer.

2026 is the year the consumer (finally) becomes king in healthcare and that’s the future we’re driving at Hims & Hers. Read more on what I expect out of the new year here, including important disclaimers:

https://t.co/YjPu6mwYef

[TBPN @tbpn]

.@AndrewDudum on the culture at $HIMS:

"The team has a stomach of steel. Whether the stock's $70 or $2.87, most of the executive team and myself will retire here."

"We're a team that's heads down and focuses on what can be accomplished in the next decade, not the next quarter."

[Hims & Hers Comms @HimsHersComms]

You shouldn’t have to guess how healthy you are or what steps you can take to stay healthy. Starting today, you don’t have to.

Introducing Labs by Hims & Hers. With comprehensive testing, clear results, and doctor-developed action plans, we’re making staying healthy accessible, proactive, and personal.

This is how we bring a whole new level of insight and support that has historically been reserved for the privileged few. Here’s what to know from this morning’s announcement:

https://t.co/318dXGywDl

[Hims & Hers Comms @HimsHersComms]

We talked to nearly 2,400 customers and 94% rated their care experience as equal to or better than in-person care.

That’s the power of telehealth when clinical excellence, quality, safety, and innovation come together in one care model.

Read more here: https://t.co/WXYRcarwjG

[Hims & Hers Comms @HimsHersComms]

Half of California will go through menopause. Zero excuses not to expand access to care.

@JShepherd_MD lays it out in @sfchronicle, calling on @CAgovernor to sign bipartisan legislation covering 22 million women.

Full piece 👉 https://t.co/iOcPmlymBA

[andrewdudum @AndrewDudum]

Around 100 FDA letters went out last week to companies across the industry as part of the administration’s recent push on pharmaceutical marketing. We got one. A number of big pharma companies received them. With this industry-wide push, the FDA is demonstrating its commitment to ensuring individuals can make informed choices about their care – a commitment we share and something Hims & Hers was built to do. We have a long history of working with regulators to keep customers safe, and I’m looking forward to continuing that work with the FDA. Want to learn more? All the letters are here: https://t.co/SgcwonYc2j

[Dan Kenger @dankenger]

On Sunday, we launched our latest campaign in the NYT and WSJ, spotlighting something we believe deeply: patient choice matters.
Your health, your terms.
Keep an eye out—more powerful print ads are on the way. $hims

[andrewdudum @AndrewDudum]

I spoke with @ByDanielGilbert at @washingtonpost for a story out today. This is a pivotal moment for healthcare: one where we can choose a future built on access, affordability, and patients as individuals. It’s not just about innovation, it’s about empowering providers and patients, expanding choice, and putting people at the center of care. The companies that lean into that future will help shape a system that truly works for everyone. Full story here: https://t.co/XtkqqXEb5b

[Bloomberg @business]

Hims & Hers Health won’t back down from selling cheap weight-loss shots, its CEO said after Novo Nordisk abruptly ended its distribution partnership https://t.co/iQ5XiXaNc0

[andrewdudum @AndrewDudum]

What launches tomorrow took many years to perfect. From the industrial design of the machines to the safety procedures delivering consistency and quality.

Tomorrow’s a small glimpse into the future of what we’re building. What I believe is one aspect of the future of healthcare. It’s one step of many towards a world where feeling great is effortless, enjoyable and empowering.

Sometimes the inspiration for innovation lives in plain site.

“An apple a day” they used to say.

I think they might have been right.

$hims

[andrewdudum @AndrewDudum]

Early results from our personalized GLP-1 program are in: in a study of over 90,000 participants, we’re seeing 60% clinical adherence and retention after 3 months, meaningfully surpassing benchmarks available to date on commercially available doses.

Personalized dosing is driving real results for those who are clinically eligible. (Not to mention, 5% average weight loss in two months and 96% reporting broader health benefits!)

More data coming soon! The 12-mo cohorts showing some incredible results.

[andrewdudum @AndrewDudum]

Fresh off our largest capital raise to date, today we’re announcing plans to acquire ZAVA, a leading digital health platform in Europe. This acquisition strengthens our leadership in the UK and establishes a presence in Germany, France, and Ireland, significantly accelerating our international expansion, with additional markets on the horizon.

Our ambition is clear: to build one of the world’s first truly global healthcare platforms, seamless, affordable, and built around the individual. With this move, we are scaling faster and expanding access to high-quality, personalized care to millions more people worldwide.

Wherever you are, whoever you are, better care should be within reach. And this is only the beginning.

https://t.co/8vsFTOeyp8

[andrewdudum @AndrewDudum]

I'm thrilled to share that through our continued long-term collaboration with @novonordisk, starting today, we're making Wegovy® eligible for Hims & Hers customers at $549/month for 6 months. Our focus is on delivering safe, convenient, and affordable care at scale, and that includes expanding access to critical obesity treatments. Working with Novo expands our commitment to holistic weight loss care, offering sustainable, long-term solutions that work at a more affordable price. More info here: https://t.co/OyIiOVVRAG

[andrewdudum @AndrewDudum]

We just shared our Q1 results. And our 2030 target: $6.5B in revenue, $1.3B in adjusted EBITDA. We're entering a new era of growth: deeper personalization, broader impact, and faster execution. The foundation is set. The roadmap is clear. We're just getting started.